Vyriad

Vyriad is a clinical-stage biotechnology company developing targeted genetic therapies for cancer and other serious diseases. From its funding announcement.

$25M Series BRaised 9 months agoRochester, USABiotech & PharmaUSA
Visit website →

In their own words

What Vyriad says it is doing

Work here? Claim your company profile

Public signal Described in the funding announcement as "clinical-stage biotechnology company developing targeted genetic therapies for cancer and other serious diseases". Source

Research and development

Public signal Read from the company's own description of what the funding supports.

Why now

Where Vyriad is today

Vyriad announced a Series B round of $25M on 2 January 2026, led by Mr.

Latest round
Series B
Amount
$25M
Announced
2 January 2026
Headquarters
Rochester, USA
Sector
Biotech & Pharma
Investors
Mr
Also participating
several family offices
Relevant leadership
Not stated

Momentum AfterRaise intelligence

AfterRaise Score

43
Established
0 funding signals in the last 90 days
Funding recency
9/40
announced within the last year
Round scale
16/25
round size relative to the market
Funding stage
18/20
Series B
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

Since the raise

What has happened since

  • 2 January 2026
    $25M Series B
    Led by Mr.

Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

What may happen next

What this raise could create

AfterRaise intelligenceNot a statement of fact

What may happen next

  • Research programme expansion
  • Scientific team growth
  • Accelerated hiring across functions
  • Commercial scale-up

Opportunities this could create

  • Clinical operations
  • Scientific hiring
  • Scientific advisers
  • Research operations
  • Specialist suppliers

Based on the Biotech & Pharma sector, a Series B round and the priorities the company itself set out. Not a statement of fact.

Early momentum2 connected signals
  • 2 January 2026$25M Series B announced
  • 2 January 2026Stated priority: research and development

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Open to

What Vyriad is open to

Not yet specified

Vyriad has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Opportunities

Ways to work with Vyriad

No open opportunities listed

Jobs, projects, partnerships, advisory and supplier needs appear here once the company has claimed its page and published them, and any role we read from its own job board appears automatically.

Work here? Open the first one

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Do you work at Vyriad?

Claim your company profile.

This page was created from publicly available information. A verified representative corrects the record, says what the company is building next and chooses which conversations it welcomes.

What we do not have yet: the roles and projects you have open and who leads the team. Claiming the page is how you fill those in.

Someone else requesting access does not give them ownership. Every representative is verified by a person before access is granted.

Maintaining your own company profile is free. A founder, CEO or authorised senior colleague can represent the company.

Also moving

Other Biotech & Pharma companies

See the sector